title: The selective estrogen receptor modulator, raloxifene: reproductive assessments in adult male rats.
abstract: Raloxifene HCl is a nonsteroidal, selective estrogen receptor modulator developed for postmenopausal osteoporosis. Reproductive toxicity of raloxifene was examined in adult male CD rats after the oral administration of doses of 0, 10, 30, or 100 mg/kg/d. In the first study, males (12/group) were treated for 2 weeks followed by 2 weeks without treatment. After dose administration on Day 13, 6 males/group were cohabited with untreated females (1:2) for up to 7 d. Males were killed on Day 14 or 28 (6/group each day). Sperm were collected from the right cauda epididymis and evaluated for relative concentration, motion characteristics, and breakage. The kinetics of spermatogenesis were examined by DNA flow cytometry. The left testis and epididymis were preserved for histopathologic evaluation. Females were examined for reproductive status on Gestation Day 13. In a second study, males (20/group) were treated for 7 weeks (4 weeks prior to cohabitation during a 2-week cohabitation period, and for 1 additional week). Treated males were cohabited with untreated females (1:1). On Gestation Day 20, untreated females were examined for reproductive status and fetuses were examined for viability, weight, gender, and morphology. At necropsy, male reproductive tissues were collected, weighed, and preserved for histopathologic evaluation. In both studies, male body weight gain and food consumption were depressed at all dose levels. There was no indication in either study that raloxifene caused important changes in sperm production, sperm quality, or male reproductive performance at doses as high as 100 mg/kg/d.
authors.affiliation: Toxicology and Drug Disposition, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfield, Indiana 46140, USA. J.A.Hoyt@Lilly.com
authors.forename: J A
authors.initials: JA
authors.lastname: Hoyt
authors.forename: L F
authors.initials: LF
authors.lastname: Fisher
authors.forename: D K
authors.initials: DK
authors.lastname: Swisher
authors.forename: R A
authors.initials: RA
authors.lastname: Byrd
authors.forename: P C
authors.initials: PC
authors.lastname: Francis
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005069:Evaluation Studies as Topic; D005260:Female; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D011003:Ploidies; D020849:Raloxifene Hydrochloride; D051381:Rats; D011960:Receptors, Estrogen / Q000819:agonists / Q000187:drug effects*; D012098:Reproduction / Q000187:drug effects*; D012741:Sexual Maturation; D013737:Testis / Q000187:drug effects
chemical_list: D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; D020849:Raloxifene Hydrochloride